A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06561685

Public ClinicalTrials.gov record NCT06561685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations

Study identification

NCT ID: NCT06561685
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 340 participants

Conditions and interventions

Conditions

Interventions

Carboplatin Drug
Cisplatin Drug
LY4050784 Drug
Nab paclitaxel Drug
Paclitaxel Drug
Pembrolizumab Drug
Pemetrexed Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 18, 2024
Primary completion: Sep 30, 2027
Completion: Sep 30, 2027
Last update posted: Apr 19, 2026

2024 – 2027

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
UCLA	Santa Monica	California	90404	Recruiting
University of Colorado Health Hospital	Aurora	Colorado	80045	Recruiting
Sarah Cannon Research Institute at HealthOne	Denver	Colorado	80218	Recruiting
Florida Cancer Specialists ORLANDO/DDU	Lake Mary	Florida	32746	Active, not recruiting
University of Miami	Miami	Florida	33136	Recruiting
University of Chicago	New Lenox	Illinois	60451	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Columbia University Medical Center	New York	New York	10032	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Ohio State University Hospital	Columbus	Ohio	43210	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232-6307	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting
USO-Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06561685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06561685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →